Clinical Trial Update: BNO 1030 Extract (Imupret) in the Treatment of Mild Forms of COVID-19 [Phase 4]

View source ↗

Summary

Phase 4 trial assessing BNO 1030 Extract (Imupret) for mild COVID-19; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anosmia
• Cough
• Fever
• Myalgia
• Nasal Congestion
• Nasopharyngitis

Drugs mentioned

• BNO 1030 Extract (Imupret) (Imupret)

Snippet

Sponsor: Ivano-Frankivsk National Medical University | Conditions: Covid19, Nasopharyngitis | Phase 4 | Status: COMPLETED